Specific Pharma A/S and Oncoscience GmbH launch a Named Patient Program for the treatment of cancer with nimotuzumab.
Oncoscience | November 6th, 2020
Specific Pharma announced today that it has entered into a supply and distribution collaboration with German based Oncoscience GmbH regarding the distribution of CIMAher® (nimotuzumab) in the Nordics. Specific Pharma will distribute CIMAher® in Denmark, Sweden, Finland, Norway and Iceland on a named patient basis. The Named Patient Supply Program will enable oncologists in the Nordics to obtain access to nimotuzumab, (5mg/ml solution for infusion) via Specific Pharma for the treatment of various types of cancer.
Nimotuzumab has been approved in 27 countries globally for a variety of cancers, including: head & neck cancer, nasopharyngeal carcinoma, pancreatic cancer, esophageal cancer and high-malignant glial cancers (glioblastoma multiform and anaplastic astrocytoma)). Nimotuzumab has also been approved in a number of countries for high-grade gliomas in children and adolescents such as Diffuse Intrinsic Pontine Glioma (DIPG).
Specific Pharma’s Director, Uffe K. Jensen says, “We are pleased to help secure access to nimotuzumab via a Named Patient Program for patients in need. Our team of driven, caring, determined, and highly skilled professionals will go above and beyond to provide patients and physicians access to nimotuzumab. Our mission is to bring value to medical professionals, so they are able to treat their patients with medication that would otherwise be unavailable to them.”
Nimotuzumab has an EU orphan designation for the treatment of pancreatic cancer and glioma and has been used in EU under named patient basis, following special individual approvals from national regulatory authorities, as it has not yet received marketing authorization in EU.
All requests must be submitted by a Clinical Oncologist on behalf of a patient. Further details on the Nimotuzumab Named Patient Program is available to healthcare professionals by contacting Specific Pharma on the details below.
Dr. Dirk Reuter, the Managing Director of Oncoscience GmbH added, “The capabilities of Specific Pharma makes them a very suitable partner for us in the Nordics, and we look forward to working together to improve the access of CIMAher® (nimotuzumab) in the Nordic region through the appropriate channels.”
Specific Pharma A/S
Uffe Kåre Jensen
T: +45 36454505
For inquiries and procurement, please contact firstname.lastname@example.org
Dr. Dirk Reuter
Tel.: +49 40 300 9799-0
Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). To date nimotuzumab has been administered to more than 140,000 patients globally and has undergone 85 clinical studies. Nimotuzumab has been approved and is currently available as a treatment in 27 countries around the world and has been provided on a compassionate basis or named patient basis in Europe and North America. The cumulative safety data for nimotuzumab suggests a more benign side-effect profile compared to currently approved EGFR targeting antibodies and small molecules. The absence of any cases of severe rash to date and the rare instances of any of the other debilitating side effects holds the prospect of nimotuzumab to become best-in-class for this important family of EGFR- targeting agents.
About Specific Pharma A/S
Specific Pharma A/S is a Danish company with focus on global sourcing and distribution of unlicensed medicines as well as medicines for special purposes such as clinical trials and situations of drug shortages. In 2010, Specific Pharma was founded as a fully owned subsidiary of Nomeco A/S, a part of Phoenix group. Today, Specific Pharma is a leading European supplier of unlicensed medicines and a preferred partner for sourcing of medicines for special needs.
Specific Pharma has a strong commitment to secure the supply of products to patients with unmet medical needs – in close cooperation with the medical profession, authorities and partners. Specific Pharma’s main concerns is to bring others value.
For more information, please visit www.Specificpharma.com
About Oncoscience GmbH
Oncoscience is a Germany based privately-owned biopharmaceutical company founded in 2001 to advance the development of novel products for the treatment of orphan indications in oncology. Oncoscience has the exclusive rights for the anti-EGFR monoclonal antibody nimotuzumab, in the European Union and the surrounding area (in total 46 countries). Oncoscience is committed to further developing nimotuzumab in Europe to address oncological diseases for which the unmet medical need is high and for which effective and safe therapy is urgently needed.